RSRyan L. Steinberg

Ryan L. Steinberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ryan L. Steinberg has a total of 133 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    From Beepers to Banners: Assessment of the Transition from an Alphanumeric Paging System to a Secure Messaging Platform from a Urology Resident Perspective

    by Reid Stubbee, Ryan L. Steinberg, Kenneth Nepple, Gina Lockwood

    IntroductionTransition from alphanumeric paging in hospital communication systems to two-way secure messaging is increasing in prevalence. This study aims to compare the impact on urology residents transitioning from alphanumeric paging to secure messaging (Epic Secure Chat, Verona, WI).MethodsSecure messaging was implemented at a large tertiary care academic medical center in April 2024. Alphanumeric paging remained active. The total number of communications received by urology residents per shift was recorded before and after implementation. A survey was distributed to urology residents who serve as the primary point of contact to assess satisfaction with communication systems prior to and at 3- and 6-months post-implementation (n=9; PGY 1-3). Plan-do-study-act (PDSA) cycles were used to target areas of improvement between post-implementation months 3 and 6.ResultsThe total number of communications received by the on-call urology resident increased by 175-339% depending on shift type. Survey data suggested that secure messaging improved resident perception of the ability to contact and communicate with physician teams and ancillary staff. Diminished satisfaction was noted with the ease of triaging message priority and the difficulty being alerted to notifications during specific time periods (e.g., overnight call, operating room).ConclusionsAt a large academic medical center, the number of communications to urology residents increased with transition from an alphanumeric paging system to a secure messaging system. Secure messaging facilitates ease of communication amongst different hospital staff. Appropriate message triage was challenging and necessitated targeted improvement efforts after initial implementation. Further study is required to optimize these systems.

  • Open Access

    Variants of unknown significance are common in brushite stone formers undergoing genetic testing for nephrolithiasis

    by Tomas Paneque, Kyle Berst, Meenakshi Sambharia, Melissa Swee, Mycah Kimble, M. Adela Mansilla, Margaret Freese, Christie P. Thomas, Chad R. Tracy, Ryan L. Steinberg

    Up to 40% of all kidney stone disease may have an underlying genetic contribution. Brushite stone formers are known to have high rates of stone recurrence and urine chemistry abnormalities, suggesting a possible intrinsic kidney abnormality which may contribute to brushite stone formation. In this study, we sought to determine the burden of genetic variants amongst brushite stone formers. An IRB approved prospective study of brushite stone formers was conducted. Patients with any brushite on stone analysis were eligible for enrollment. Genetic testing was done on peripheral blood derived DNA and assessed using a clinically available nephrolithiasis gene panel. Primary analysis assessed rates of genetic variants amongst brushite stone formers. Secondary analysis assessed for distinct patterns in urine chemistries in different genotypes. 15 patients (8 males) with a median age of 32 years (range 22–69) underwent genetic testing. 12 patients (80%) were reported to have a genetic variant, with 6 (40%) having multiple variants. Two patients had a heterozygous pathogenic or likely pathogenic variant in a gene that causes autosomal recessive disease. 9 (60%) patients had a variant of unknown significance. 10 (67%) patients had genetic variants associated with hypophosphatemic rickets. Genetic variants of unknown significance are common in brushite stone formers. Further work is needed to assess the significance of these variants and their role in the lithogenic process.


  • Open Access

    The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC

    by Ian M McElree, Ryan L Steinberg, Sarah L Mott, Helen Y Hougen, Michael A O'DOnnell, Vignesh T Packiam

    Background: During surveillance of high-risk non-muscle invasive bladder cancer (HR-NMIBC), occult disease can be missed by standard cystoscopy. Objective: To determine the utility of enhanced restaging procedures. Methods: We retrospectively reviewed 297 patients with HR-NMIBC who underwent enhanced restaging procedures during the first surveillance following induction intravesical therapy between 2010–2021. Patients were stratified by number of induction treatments with unique agents (161, 63, and 73 patients with 1, 2, and 3+ treatments) and analyzed using exact logistic regression models. Enhanced restaging procedures included standard cystoscopy (white-light cystoscopy with bladder wash cytology) plus additional components including blue-light cystoscopy, mapping bladder biopsies, retrograde pyelograms, upper tract cytologies, and prostatic urethral biopsies. Results: When standard cystoscopy was negative, blue light cystoscopy detected occult bladder cancer in 6.0%, 7.4%, and 19% of patients in the 1, 2, and 3+ treatment groups. History of CIS was associated with increased detection with blue light (p = 0.03). Extravesical (upper tract or prostatic urethral) cancer was detected by additional restaging components in 0.6%, 1.7%, and 15% of patients with 1, 2, and 3+ intravesical treatments. On multivariable analysis, receipt of 3+ intravesical inductions increased the odds of having at least one additional restaging component identify cancer (HR 3.76; p < .01). Conclusions: Blue light cystoscopy improves surveillance of HR-NMIBC, particularly in those with CIS. Additional restaging procedures improved detection of extravesical disease in patients with heavier pre-treatment history. Risk-adapted utilization of enhanced restaging procedures requires further study.


  • Open Access

    Current and perceived optimal use of point-of-care ultrasound in urology

    by Charles H. Schlaepfer, Zubin Shetty, Vignesh T. Packiam, Chad R. Tracy, Elizabeth B. Takacs, Ruslan Korets, Ryan L. Steinberg

    Introduction: Point-of-care ultrasound (POCUS) is a valuable tool for clinicians, but little data exists regarding the perceptions of ideal POCUS utilization, as compared to actual use, amongst urologists. We aim to assess how perceptions align or diverge with actual practice. Methods: An institutional review board (IRB)-approved survey was developed and disseminated by email to 6 of 8 American Urologic Association Sections, program directors via the Society of Academic Urologists, and to 2 residency programs. The primary outcome was to assess differences in current and perceived optimal use. Data was collected via the University of Iowa RedCap system. Descriptive statistics and Chi-squared analyses were performed. Results: 184 non-trainees and 41 trainees completed the survey. Rates of current POCUS use were significantly lower than perceived optimal usage for renal (58% to 88%, p < 0.001), testis (37% to 74%, p < 0.001), and penile (19% to 37%, p < 0.001) application amongst the urologic organs. Current use was also lower than perceived optimal use with regard to utilization in the emergency room (16% to 39%, p < 0.001) and for diagnostic purposes (53% to 81%, p < 0.001), regardless of organ focus. Sub-analysis found that trainees, compared to non-trainees, identified the inpatient unit (54% to 18%, p < 0.001) and emergency room (81% to 35%, p < 0.001) as optimal locations for use. Conclusions: Perceptions of POCUS use differ between trainees and non-trainees, especially the location of use. These results help identify areas for which training could be focused, as well as highlight the need for further research on generational variation in desired POCUS use.

  • Open Access

    Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma

    by Ian M. McElree, Vignesh T. Packiam, Ryan L. Steinberg, Helen Y. Hougen, Mohamad Abou Chakra, Sarah L. Mott, Michael A. O’donnell

    Background: After first-line treatment failure, patients with non-muscle invasive urothelial carcinoma (NMIUC) are recommended to undergo radical cystectomy. However, those unable to pursue radical surgery or desiring bladder preservation require effective salvage therapies. Multi-agent treatment regimens are particularly useful for targeting the complex resistance mechanisms of recurrent UC. Herein, we report a regimen of sequential doxorubicin and gemcitabine alternating weekly with sequential docetaxel and mitomycin (Quad Chemo) for patients with recurrent high-risk NMIUC. Materials and Methods: We retrospectively identified all patients sequentially treated with 50 mg of doxorubicin followed by 1000 mg of gemcitabine alternating weekly with sequential 37.5 mg of docetaxel followed by 40 mg mitomycin-C between 2007–2024. Induction consisted of 8 weekly treatments, and, if disease-free, patients were initiated on monthly maintenance treatments for 2 years. Results: In total, 29 patients (39 treated units; 26 lower urinary tract, 13 upper urinary tract) with high-grade NMIUC were included in the final analysis. The cohort had high-risk features with a median of three prior induction therapies and with 38 (97%) units presented with either biopsy-proven CIS or presumed CIS in the context of high-grade urine cytology in the absence of tumorous lesions. There were 26 recurrences during follow-up, 17 in the lower tract and 9 in the upper tract. Among all of the treated units, the complete response rate was 80%, and 1- and 2-year recurrence-free survival was 60% and 43%, respectively. In total, 10 patients experienced disease progression yielding a 5-year progression-free survival of 57%. Five patients ultimately died due to bladder cancer yielding a 5-year cancer-specific survival of 83%. A total of 19 (66%) patients reported side effects during treatment, and 7 (24%) stopped treatment secondary to side effects. Conclusions: In a high-risk heavily pre-treated cohort, Quad Chemo rescued a significant portion of patients with recurrent NMIUC from disease relapse. However, progression events were considerable in the long term. Further prospective evaluation of this treatment regimen is warranted.


  • Open Access

    A pilot intervention trial to reduce the use of post-procedural antimicrobials after common endourologic surgeries

    by Daniel J. Livorsi, Vignesh T. Packiam, Qianyi Shi, Steven Y. Alberding, Knute D. Carter, James A. Brown, James B. Mason, Jeffrey P. Weiss, Ryan L. Steinberg

    Objective: Post-procedural antimicrobial prophylaxis is not recommended by professional guidelines but is commonly prescribed. We sought to reduce use of post-procedural antimicrobials after common endoscopic urologic procedures.Design: A before-after, quasi-experimental trial with a baseline (July 2020–June 2022), an implementation (July 2022), and an intervention period (August 2022–July 2023).Setting: Three participating medical centers.Intervention: We assessed the effect of a bundled intervention on excess post-procedural antimicrobial use (ie, antimicrobial use on post-procedural day 1) after three types of endoscopic urologic procedures: ureteroscopy and transurethral resection of bladder tumor or prostate. The intervention consisted of education, local champion(s), and audit-and-feedback of data on the frequency of post-procedural antimicrobial-prescribing.Results: 1,272 procedures were performed across all 3 sites at baseline compared to 525 during the intervention period; 644 (50.6%) patients received excess post-procedural antimicrobials during the baseline period compared to 216 (41.1%) during the intervention period. There was no change in the use of post-procedural antimicrobials at sites 1 and 2 between the baseline and intervention periods. At site 3, the odds of prescribing a post-procedural antimicrobial significantly decreased during the intervention period relative to the baseline time trend (0.09; 95% CI 0.02–0.45). There was no significant increase in post-procedural unplanned visits at any of the sites.Conclusions: Implementation of a bundled intervention was associated with reduced post-procedural antimicrobial use at one of three sites, with no increase in complications. These findings demonstrate both the safety and challenge of guideline implementation for optimal perioperative antimicrobial prophylaxis.This trial was registered on clinicaltrials.gov, NCT04196777.